Deadline Date	30/10/2018
Date Submitted	23/07/2018
Type	Performance in Delivering
NHS provider	Norfolk and Norwich University Hospitals NHS Foundation Trust

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
31552	17/YH/0116	225662	Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes	Number Agreed	7	7	Date Agreed	15/11/2017	5	15/11/2017	5	Recruitment Finished	In total 690 potential participants were Identified, 7 were approached and consented, 2 of these were post consent screen failures, 5 of these were consented and recruited. The reset were pre-screen failures.
31553	15/WS/0149	184848	A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I)	Number Agreed	5	5	Date Agreed	10/01/2018	2	10/01/2018	2	Recruitment Finished	9 potential participants indentifed 7 were pre-screen failures, 2 consented and were randomised
31554	16/LO/1810	209789	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	Number Agreed	2	2	Date Agreed	11/01/2018	2	11/01/2018	2	Recruitment Finished	
31555	15/NE/0144	179243	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN?S DISEASE PREVIOUSLY ENROLLEDIN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Number Agreed	3	3	Date Agreed	30/01/2018	0	30/01/2018	0	Recruitment Finished	
31556	14/EM/0086	146639	A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety,tolerability and efficacy up to 3 years in subjects with active Ankylosing Spondyliti	Number Agreed	4	4	Date Agreed	07/02/2018	0	07/02/2018	0	Recruitment Finished	
31557	16/NI/0129	177983	A randomised double blind (sponsor unblinded), single and repeat ascending dose First Time in Human study in healthy subjects, cold urticaria and chronic spontaneousurticaria subjects to investigate safety, tolerability, phharmacodynamics and pharmac	Number Agreed	1	1	Date Agreed	07/02/2018	1	07/02/2018	1	Recruitment Finished	
31558	16/EM/0037	196490	LY vs. Placebo with Active Control I1F-MC-RHBW: AS TNF-Experienced Phase III	Number Agreed	8	8	Date Agreed	12/02/2018	6	12/02/2018	6	Recruitment Finished	10 potential participants were identified, 6 were consented and randomised, the other 4 were approached but on talking with them were found to be inelligable for inculsion.
31559	13/NW/0003	117310	A randomized, double blind, placebo controlled phase 3 study to assess the safety and efficacy of art-123 in subjects with severe sepsis and coagulopathy (protocol number 3-001)	Number Agreed	1	1	Date Agreed	28/03/2018	0	28/03/2018	0	Recruitment Finished	This was a rare disease with a target of 1, no participants were identifed
31560	16/NI/0036	192710	Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo- Embolism Risk (MARINER)	Number Agreed	4	4	Date Agreed	02/04/2018	0	02/04/2018	0	Withdrawn By Sponsor	The national target was 9000, only 10 participants were recruited nationally
31561	16/SC/0677	217105	A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis	Number Agreed	2	2	Date Agreed	19/04/2018	1	19/04/2018	1	Recruitment Finished	5 participants were identified, 4 were approached and declined, 1 was consented and randomised
31562	17/LO/0848	222163	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	Number Agreed	2	2	Date Agreed	19/04/2018	3	19/04/2018	3	Recruitment Finished	
31563	17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)	Number Agreed	2	2	Date Agreed	19/04/2018	0	19/04/2018	0	Recruitment Finished	5 participants were identified, 4 were approached and declined, 1 was consented but was a post screening failure
31564	15/EE/0260	181518	MULTICENTER, OPEN-LABEL (PART A) FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO CONTROLLED STUDY (PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) RECEIVING EITHER CERTOLIZUMAB PEGO	Number Agreed	4	4	Date Agreed	25/06/2018	3	25/06/2018	3	Recruitment Finished	
31802	15/LO/2098	182147	A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon beta-1a) and Placebo in the Treatment of Patients with Moderate to Severe Acute Respiratory Distress Syndrome	Number Agreed	6	6	Date Agreed	06/07/2018	0	06/07/2018	0	Recruitment Finished	8 participants were pre-screened but none were eligible
31803	12/WM/0149	104597	Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes	Number Agreed	1	1	Date Agreed	11/07/2018	0	11/07/2018	0	Recruitment Finished	This was a rare disease with a target of 1, no participants were identified
31804	17/YH/0040	209462	A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, 12 MONTHS, EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN? - THERAPY IN PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY	Number Agreed	2	2	Date Agreed	11/07/2018	0	11/07/2018	0	Recruitment Finished	1 participant was eligible but did not consent as they did not want additional tests
31805	16/EE/0243	207331	A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE?S DISEASE	Number Agreed	3	3	Date Agreed	17/07/2018	5	17/07/2018	5	Recruitment Finished	
31806	17/EM/0339	223211	A randomised, placebo-controlled, double-blind, parallel-group, multicentre, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with symptomatic endometriosis over a 12-week treatment period	Number Agreed	2	2	Date Agreed	24/07/2018	1	24/07/2018	1	Recruitment Finished	2 potential participants identified one consented and was recruited the other was a post consent screening failure
31807	15/YH/0535	190077	A multicenter, randomized, open label, parallel group study comparing pre-discharge and posT-discharge tReatment initiation with LCZ696 in heArt failure patieNtS with reduced ejectIon-fracTion hospItalized for an acute decOmpensation eveNt (ADHF) (the TRAN	Number Agreed	5	5	Date Agreed	30/07/2018	11	30/07/2018	11	Recruitment Finished	
31808	16/EM/0312	205489	A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 in Patients with NAFLD	Number Agreed	4	4	Date Agreed	20/08/2018	1	20/08/2018	1	Recruitment Finished	9 participants were identified and approached. 1 consented and was recruited, 2 were consented but were post consent screen failures, 6 more were approached but declined participation